Catabasis Pharmaceuticals Company Profile (NASDAQ:CATB)

About Catabasis Pharmaceuticals (NASDAQ:CATB)

Catabasis Pharmaceuticals logoCatabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CATB
  • CUSIP: N/A
  • Web: www.catabasis.com
Capitalization:
  • Market Cap: $27.88 million
  • Outstanding Shares: 22,481,000
Average Prices:
  • 50 Day Moving Avg: $1.26
  • 200 Day Moving Avg: $1.36
  • 52 Week Range: $1.08 - $7.89
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.02
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.96 per share
  • Price / Book: 1.29
Profitability:
  • EBIDTA: ($31,270,000.00)
  • Return on Equity: -115.03%
  • Return on Assets: -83.58%
Debt:
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 3.73%
  • Quick Ratio: 3.73%
Misc:
  • Average Volume: 189,966 shs.
  • Beta: 1.18
  • Short Ratio: 4.95
 

Frequently Asked Questions for Catabasis Pharmaceuticals (NASDAQ:CATB)

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) issued its earnings results on Thursday, August, 10th. The company reported ($0.32) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.40) by $0.08. View Catabasis Pharmaceuticals' Earnings History.

When will Catabasis Pharmaceuticals make its next earnings announcement?

Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Catabasis Pharmaceuticals.

Where is Catabasis Pharmaceuticals' stock going? Where will Catabasis Pharmaceuticals' stock price be in 2017?

5 brokers have issued 12-month price objectives for Catabasis Pharmaceuticals' shares. Their predictions range from $4.00 to $9.00. On average, they expect Catabasis Pharmaceuticals' stock price to reach $5.25 in the next year. View Analyst Ratings for Catabasis Pharmaceuticals.

What are analysts saying about Catabasis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Catabasis Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. " (5/19/2017)
  • 2. Wedbush analysts commented, " With numerical improvements in all function-associated endpoints observed in Part B of the MoveDMD trial, we believe extended treatment with edasalonexent (CAT-1004) could result in a deepening of the response'a potential positive sign that could boost shares. We continue to look to Q2:17 for an interim look of the MoveDMD study at 24 weeks (Part C) as the next material catalyst. Q4/FY16 Financial Update: CATB reported no revenues and GAAP EPS (loss) of $(0.47)/$(2.22) vs. consensus of $(0.49)/$(2.25). CATB ended 2016 with ~$38.5 million in cash and cash equivalents and we project runway through Q1:18, in line with company guidance." (3/20/2017)

Who are some of Catabasis Pharmaceuticals' key competitors?

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the folowing people:

  • Kenneth M. Bate, Co-Chairman of the Board
  • Michael Jay Ross Ph. D., Director, Co-Chairman of the Board of Directors
  • Jill C. Milne Ph.D., President, Chief Executive Officer, Co-Founder, Director
  • Deirdre A. Cunnane J.D., Senior Vice President, General Counsel, Treasurer
  • Andrew Nichols Ph.D., Chief Scientific Officer
  • Joanne M. Donovan M.D. Ph.D., Chief Medical Officer
  • Edward Hibben, Chief Business Officer
  • Burt A. Adelman M.D., Independent Director
  • Jean M. George, Independent Director
  • Michael D. Kishbauch, Independent Director

When did Catabasis Pharmaceuticals IPO?

(CATB) raised $60 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 4,300,000 shares at $13.00-$15.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

Who owns Catabasis Pharmaceuticals stock?

Catabasis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include SV Health Investors LLC (12.72%), Clarus Ventures LLC (12.25%), Sphera Funds Management LTD. (1.28%), Vanguard Group Inc. (1.06%), Virtu KCG Holdings LLC (0.85%) and Oppenheimer & Co. Inc. (0.53%). View Institutional Ownership Trends for Catabasis Pharmaceuticals.

Who sold Catabasis Pharmaceuticals stock? Who is selling Catabasis Pharmaceuticals stock?

Catabasis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Sphera Funds Management LTD.. View Insider Buying and Selling for Catabasis Pharmaceuticals.

Who bought Catabasis Pharmaceuticals stock? Who is buying Catabasis Pharmaceuticals stock?

Catabasis Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Virtu KCG Holdings LLC and Oppenheimer & Co. Inc.. View Insider Buying and Selling for Catabasis Pharmaceuticals.

How do I buy Catabasis Pharmaceuticals stock?

Shares of Catabasis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catabasis Pharmaceuticals' stock price today?

One share of Catabasis Pharmaceuticals stock can currently be purchased for approximately $1.24.


MarketBeat Community Rating for Catabasis Pharmaceuticals (NASDAQ CATB)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  140 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  199
MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Catabasis Pharmaceuticals (NASDAQ:CATB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $5.25 (323.39% upside)

Analysts' Ratings History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/15/2017Oppenheimer Holdings, Inc.Lower Price TargetOutperform$9.00 -> $4.00HighView Rating Details
8/14/2017HC WainwrightBoost Price TargetBuy$8.00 -> $9.00MediumView Rating Details
6/21/2017WedbushReiterated RatingOutperform$4.00HighView Rating Details
2/1/2017Citigroup Inc.DowngradeBuy -> NeutralN/AView Rating Details
2/1/2017Cowen and CompanyDowngradeOutperform -> Market Perform$4.00N/AView Rating Details
(Data available from 8/21/2015 forward)

Earnings

Earnings History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Earnings by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)
Earnings History by Quarter for Catabasis Pharmaceuticals (NASDAQ CATB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.33)N/AView Earnings Details
8/10/2017Q2 2017($0.40)($0.32)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.49)($0.47)ViewN/AView Earnings Details
11/10/2016Q316($0.65)($0.54)ViewListenView Earnings Details
8/11/2016Q216($0.65)($0.61)ViewListenView Earnings Details
5/12/2016Q1($0.64)($0.61)ViewListenView Earnings Details
3/2/2016Q415($0.69)($0.63)ViewListenView Earnings Details
11/12/2015Q315($0.64)($0.55)ViewListenView Earnings Details
8/13/2015Q2 2015($0.70)($0.53)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Catabasis Pharmaceuticals (NASDAQ:CATB)
2017 EPS Consensus Estimate: ($1.46)
2018 EPS Consensus Estimate: ($1.21)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.44)($0.44)($0.44)
Q2 20171($0.35)($0.35)($0.35)
Q3 20172($0.35)($0.31)($0.33)
Q4 20172($0.36)($0.32)($0.34)
Q1 20181($0.26)($0.26)($0.26)
Q2 20181($0.31)($0.31)($0.31)
Q3 20181($0.32)($0.32)($0.32)
Q4 20181($0.32)($0.32)($0.32)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Catabasis Pharmaceuticals (NASDAQ:CATB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Insider Ownership Percentage: 64.10%
Institutional Ownership Percentage: 32.93%
Insider Trades by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)
Institutional Ownership by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)
Insider Trades by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/30/2015Medimmune Ventures, Inc.Major ShareholderBuy223,439$12.00$2,681,268.00View SEC Filing  
6/30/2015Nicholas GalakatosDirectorBuy376,695$12.00$4,520,340.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Catabasis Pharmaceuticals (NASDAQ:CATB)
Latest Headlines for Catabasis Pharmaceuticals (NASDAQ:CATB)
Source:
DateHeadline
americanbankingnews.com logoWedbush Weighs in on Catabasis Pharmaceuticals, Inc.'s Q3 2017 Earnings (CATB)
www.americanbankingnews.com - August 16 at 7:22 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Catabasis Pharmaceuticals, Inc. Lifted by Analyst (CATB)
www.americanbankingnews.com - August 16 at 7:18 AM
americanbankingnews.com logoOppenheimer Holdings, Inc. Trims Catabasis Pharmaceuticals, Inc. (CATB) Target Price to $4.00
www.americanbankingnews.com - August 15 at 4:52 PM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Price Target Increased to $9.00 by Analysts at HC Wainwright
www.americanbankingnews.com - August 14 at 7:38 AM
seekingalpha.com logoCatabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 11 at 10:29 PM
finance.yahoo.com logoEdited Transcript of CATB earnings conference call or presentation 10-Aug-17 8:30pm GMT
finance.yahoo.com - August 11 at 10:29 PM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (CATB) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 11 at 3:58 PM
finance.yahoo.com logoCatabasis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Reviews Business Progress
finance.yahoo.com - August 10 at 6:08 PM
finance.yahoo.com logoCatabasis Pharmaceuticals posts 2Q loss
finance.yahoo.com - August 10 at 6:08 PM
businesswire.com logoCatabasis Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference - Business Wire (press release)
www.businesswire.com - August 9 at 5:09 PM
finance.yahoo.com logoCatabasis Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 9 at 5:09 PM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 4 at 8:52 AM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (CATB) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:20 AM
finance.yahoo.com logoCatabasis Pharmaceuticals to Report Second Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, August 10
finance.yahoo.com - July 27 at 4:21 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Yandex, Delta Air Lines, Target ... - Nasdaq
www.nasdaq.com - July 13 at 3:39 PM
americanbankingnews.com logo Analysts Expect Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Will Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - July 12 at 8:18 AM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 10 at 8:46 AM
nasdaq.com logoSarepta Appoints Ex-Allergan Executive as CEO and President - Nasdaq
www.nasdaq.com - June 29 at 6:07 PM
streetinsider.com logoCatabasis Pharma (CATB) to Present Results from MoveDMD Trial ... - StreetInsider.com
www.streetinsider.com - June 23 at 9:48 PM
streetinsider.com logoCatabasis Pharma (CATB) to Present Results from MoveDMD Trial of Edasalonexent (CAT-1004) at PPMD
www.streetinsider.com - June 23 at 4:45 PM
finance.yahoo.com logoCatabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent (CAT-1004) at the 2017 PPMD Annual Connect Conference
finance.yahoo.com - June 23 at 4:45 PM
americanbankingnews.com logoWedbush Reaffirms "Outperform" Rating for Catabasis Pharmaceuticals, Inc. (CATB)
www.americanbankingnews.com - June 21 at 7:42 AM
americanbankingnews.com logo Brokerages Anticipate Catabasis Pharmaceuticals, Inc. (CATB) Will Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - June 16 at 11:16 AM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (CATB) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - June 13 at 7:45 AM
streetinsider.com logoCatabasis Pharma (CATB) Presents New Data for CAT-5571 as Novel Potential Oral Treatment for CF at 40th ECFS
www.streetinsider.com - June 9 at 4:46 PM
streetinsider.com logoCatabasis Pharma (CATB) Presents New Data for CAT-5571 as ... - StreetInsider.com
www.streetinsider.com - June 8 at 10:09 PM
finance.yahoo.com logoCatabasis Pharmaceuticals Presents New Data for CAT-5571 as a Novel Potential Oral Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
finance.yahoo.com - June 8 at 5:07 PM
americanbankingnews.com logoShort Interest in Catabasis Pharmaceuticals Inc (CATB) Expands By 4.5%
www.americanbankingnews.com - June 3 at 5:28 PM
finance.yahoo.com logoCatabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
finance.yahoo.com - June 2 at 5:36 PM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 19 at 5:20 PM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 19 at 7:50 AM
finance.yahoo.com logoJ&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021
finance.yahoo.com - May 18 at 11:24 AM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc to Post Q2 2017 Earnings of ($0.35) Per Share, Wedbush Forecasts (CATB)
www.americanbankingnews.com - May 17 at 8:08 AM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Forecasted to Post Q1 2018 Earnings of ($0.30) Per Share
www.americanbankingnews.com - May 16 at 10:48 AM
americanbankingnews.com logoWedbush Reiterates Ourperform Rating for Catabasis Pharmaceuticals Inc (CATB)
www.americanbankingnews.com - May 15 at 9:34 PM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Given "Outperform" Rating at Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 15 at 10:20 AM
finance.yahoo.com logoEdited Transcript of CATB earnings conference call or presentation 11-May-17 8:30pm GMT
finance.yahoo.com - May 12 at 4:42 PM
nasdaq.com logoAKTX Falls To Disgrace, CATB Awaits Data In Q3, CORI Surges On Trial Data
www.nasdaq.com - May 12 at 2:48 AM
seekingalpha.com logoCatabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 9:47 PM
bizjournals.com logoTechnical Reports on Biotech Stocks -- Celsion, Incyte, ImmunoGen, and Catabasis Pharma
www.bizjournals.com - May 11 at 9:47 PM
businesswire.com logoCatabasis Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Business Progress - Business Wire (press release)
www.businesswire.com - May 11 at 4:45 PM
prnewswire.com logoTechnical Reports on Biotech Stocks -- Celsion, Incyte, ImmunoGen, and Catabasis Pharma - PR Newswire (press release)
www.prnewswire.com - May 11 at 4:45 PM
finance.yahoo.com logoInvestor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call
finance.yahoo.com - May 11 at 4:45 PM
finance.yahoo.com logoCatabasis Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Business Progress
finance.yahoo.com - May 11 at 4:45 PM
finance.yahoo.com logoCatabasis Pharmaceuticals posts 1Q loss
finance.yahoo.com - May 11 at 4:45 PM
americanbankingnews.com logoCatabasis Pharmaceuticals Inc (CATB) Expected to Post Earnings of -$0.45 Per Share
www.americanbankingnews.com - May 4 at 1:37 AM
americanbankingnews.com logoCatabasis Pharmaceuticals (CATB) Earning Positive Media Coverage, Report Finds
www.americanbankingnews.com - May 2 at 12:24 PM
americanbankingnews.com logoShort Interest in Catabasis Pharmaceuticals Inc (CATB) Declines By 25.1%
www.americanbankingnews.com - April 29 at 8:52 AM
americanbankingnews.com logoCatabasis Pharmaceuticals (CATB) Earns Daily News Impact Score of 0.28
www.americanbankingnews.com - April 28 at 11:58 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Catabasis Pharmaceuticals Inc (CATB) Will Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - April 28 at 8:55 AM

Social

Chart

Catabasis Pharmaceuticals (CATB) Chart for Monday, August, 21, 2017

This page was last updated on 8/21/2017 by MarketBeat.com Staff